CTLA4 and neoplasm: However, only a minority of patients robustly and durably respond to these therapies, and while combined targeting of PD-1 and CTLA-4 enhances tumor regression, it is also associated with significantly more adverse events (Chae et al., 2018; Curran et al., 2010; Postow et al., 2015).